UK companies Molecular Profiles and XenoGesis forge partnership

Published: 31-Jul-2014

Nottingham-based companies will support drug developers during pre-clinical and formulation stages

Molecular Profiles, a UK contract development and manufacturing organisation, is collaborating with XenoGesis to support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.

Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound’s bioavailability.

The alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates, which have solubility issues during formulation development.

Frank Condella, President and Chief Executive of Columbia Laboratories, said the two companies have complementary service offerings, which will allow them to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to Molecular Profiles' enabling technologies package.

'For us, this will build upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies,' he said.

XenoGesis, founded by Managing Director Richard Weaver, after a 15-year career at AstraZeneca, specialises in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.

Weaver said: 'Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients. We will be able to give them a better understanding of their compounds during pre-clinical work, which in turn, will reduce cost and provide a quicker route to market.'

Molecular Profiles specialises in advanced characterisation, pharmaceutical product development, clinical trials manufacturing and analytical support.

You may also like